肝性脑病的未来治疗方法。
Future Therapies of Hepatic Encephalopathy.
机构信息
Division of Gastroenterology and Hepatology, New York/Presbyterian-Weill Cornell Medical College, 1305 York Avenue, 4th Floor, New York, NY 10021, USA.
Division of Gastroenterology and Hepatology, New York/Presbyterian-Weill Cornell Medical College, 1305 York Avenue, 4th Floor, New York, NY 10021, USA.
出版信息
Clin Liver Dis. 2024 May;28(2):331-344. doi: 10.1016/j.cld.2024.02.002.
Abstract
Hepatic encephalopathy, either covert or overt, affects more than half of patients with cirrhosis and has lasting effects even after portal hypertension is corrected. Unfortunately, the current therapeutic options still result in high rates of relapse and progression, in part owing to cost barriers and side effects, leading to poor adherence. This review summarizes emerging treatment options, which could take advantage of alternative disease pathways to improve future care of those with hepatic encephalopathy.
摘要
肝性脑病，无论是隐袭性还是显性的，影响了一半以上的肝硬化患者，即使在门静脉高压得到纠正后，仍有持久的影响。不幸的是，目前的治疗选择仍然导致高复发率和进展率，部分原因是由于成本障碍和副作用，导致患者的依从性差。这篇综述总结了新出现的治疗选择，这些选择可以利用替代疾病途径，改善肝性脑病患者的未来护理。
相似文献
1
Future Therapies of Hepatic Encephalopathy.肝性脑病的未来治疗方法。
Clin Liver Dis. 2024 May;28(2):331-344. doi: 10.1016/j.cld.2024.02.002.
2
Effects of raloxifene on portal hypertension and hepatic encephalopathy in cirrhotic rats.雷洛昔芬对肝硬化大鼠门静脉高压和肝性脑病的影响。
Eur J Pharmacol. 2017 May 5;802:36-43. doi: 10.1016/j.ejphar.2017.02.039. Epub 2017 Feb 24.
3
Novel approaches in the medical management of compensated cirrhosis.代偿期肝硬化的医学治疗新方法。
Expert Rev Gastroenterol Hepatol. 2024 Jun;18(6):239-256. doi: 10.1080/17474124.2024.2358149. Epub 2024 May 28.
4
Hepatic encephalopathy.肝性脑病。
Saudi J Gastroenterol. 2012 Sep-Oct;18(5):301-9. doi: 10.4103/1319-3767.101123.
5
Hepatic encephalopathy in non-cirrhotic portal hypertension.非肝硬化性门静脉高压症中的肝性脑病
Metab Brain Dis. 2025 Jan 16;40(1):103. doi: 10.1007/s11011-024-01522-5.
6
[Therapy of chronic hepatitis and liver cirrhosis and their complications. 2. Treatment of portal hypertension and hepatic coma].[慢性肝炎和肝硬化及其并发症的治疗。2. 门静脉高压症和肝昏迷的治疗]
Z Arztl Fortbild (Jena). 1974 Jun 15;68(12):587-91 concl.
7
Hepatic coma in cirrhosis, portal hypertension, and following portacaval shunt. Its etiologies and the current status of its treatment.肝硬化、门静脉高压及门腔分流术后的肝昏迷。其病因及治疗现状。
Arch Surg. 1974 Mar;108(3):325-36. doi: 10.1001/archsurg.1974.01350270055010.
8
Diagnosis and Management of Hepatic Encephalopathy.肝性脑病的诊断与治疗。
Clin Liver Dis. 2021 May;25(2):393-417. doi: 10.1016/j.cld.2021.01.008. Epub 2021 Mar 11.
9
Hepatic Encephalopathy: Diagnosis and Treatment in Advanced Liver Disease.肝性脑病：晚期肝病的诊断与治疗。
Crit Care Nurs Clin North Am. 2022 Sep;34(3):331-339. doi: 10.1016/j.cnc.2022.04.011.
10
The effects of propranolol on hepatic encephalopathy in patients with cirrhosis and portal hypertension.普萘洛尔对肝硬化和门静脉高压患者肝性脑病的影响。
Aliment Pharmacol Ther. 1988 Apr;2(2):143-51. doi: 10.1111/j.1365-2036.1988.tb00681.x.
引用本文的文献
1
Hepatic encephalopathy: risk identification and prophylaxis approaches.肝性脑病：风险识别与预防方法
Metab Brain Dis. 2025 Mar 7;40(3):138. doi: 10.1007/s11011-025-01531-y.
本文引用的文献
1
Secondary Ammonia Scavenge With Glycerol Phenylbutyrate Improves Hyperammonemia Following Portosystemic Shunting.用苯丁酸钠甘油进行继发性氨清除可改善门体分流术后的高氨血症。
JPGN Rep. 2022 Jun 21;3(3):e210. doi: 10.1097/PG9.0000000000000210. eCollection 2022 Aug.
2
Barriers to Lactulose Adherence in Patients with Cirrhosis and Hepatic Encephalopathy.肝硬化和肝性脑病患者服用乳果糖的障碍。
Dig Dis Sci. 2023 Jun;68(6):2389-2397. doi: 10.1007/s10620-023-07935-z. Epub 2023 Apr 29.
3
VE303, a Defined Bacterial Consortium, for Prevention of Recurrent Clostridioides difficile Infection: A Randomized Clinical Trial.VE303，一种特定细菌联合体，用于预防复发性艰难梭菌感染：一项随机临床试验。
JAMA. 2023 Apr 25;329(16):1356-1366. doi: 10.1001/jama.2023.4314.
4
A double-blind randomized placebo-controlled trial of albumin in outpatients with hepatic encephalopathy: HEAL study.白蛋白用于肝性脑病门诊患者的双盲随机安慰剂对照试验：HEAL研究
J Hepatol. 2023 Feb;78(2):312-321. doi: 10.1016/j.jhep.2022.09.009. Epub 2022 Sep 22.
5
Dosing of Rifaximin Soluble Solid Dispersion Tablets in Adults With Cirrhosis: 2 Randomized, Placebo-controlled Trials.利福昔明固体分散片在肝硬化成人患者中的给药：2项随机、安慰剂对照试验。
Clin Gastroenterol Hepatol. 2023 Mar;21(3):723-731.e9. doi: 10.1016/j.cgh.2022.05.042. Epub 2022 Jun 22.
6
Promises of microbiome-based therapies.基于微生物组的治疗方法的承诺。
J Hepatol. 2022 Jun;76(6):1379-1391. doi: 10.1016/j.jhep.2021.12.003.
7
Colonization of the live biotherapeutic product VE303 and modulation of the microbiota and metabolites in healthy volunteers.活体生物治疗产品 VE303 的定植及其对健康志愿者肠道菌群和代谢产物的调节。
Cell Host Microbe. 2022 Apr 13;30(4):583-598.e8. doi: 10.1016/j.chom.2022.03.016.
8
Fecal microbiota transplant improves cognition in hepatic encephalopathy and its effect varies by donor and recipient.粪便微生物移植可改善肝性脑病的认知功能，其效果因供体和受体而异。
Hepatol Commun. 2022 Aug;6(8):2079-2089. doi: 10.1002/hep4.1950. Epub 2022 Apr 5.
9
Rifaximin Modulates the Gut Microbiota to Prevent Hepatic Encephalopathy in Liver Cirrhosis Without Impacting the Resistome.利福昔明调节肠道微生物群以预防肝硬化肝性脑病，而不影响耐药组。
Front Cell Infect Microbiol. 2022 Jan 18;11:761192. doi: 10.3389/fcimb.2021.761192. eCollection 2021.
10
Rifaximin-α reduces gut-derived inflammation and mucin degradation in cirrhosis and encephalopathy: RIFSYS randomised controlled trial.利福昔明-α可减少肝硬化和肝性脑病中的肠道来源的炎症和粘蛋白降解：RIFSYS 随机对照试验。
J Hepatol. 2022 Feb;76(2):332-342. doi: 10.1016/j.jhep.2021.09.010. Epub 2021 Sep 24.
Zotero 插件